Ogeda announces positive data from Phase IIa trial of fezolinetant (ESN364) in the treatment of menopausal hot flashes

Ogeda, a clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting G-protein coupled receptors (GPCRs), has announced positive top line data from the… …read more